Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease

作者：de Boer Hetty C^*; van Solingen Coen; Prins Jurrien; Duijs Jacques M G J; Huisman Menno V; Rabelink Ton J; van Zonneveld Anton Jan

来源：European Heart Journal, 2013, 34(44): 3451-3457.

DOI：10.1093/eurheartj/eht007

• miR-126
• platelets
• aspirin
• diabetes mellitus type 2

MicroRNA-126 (miR-126) facilitates angiogenesis and regulates endothelial cell function. Recent data suggest that miR-126 can serve as a biomarker for vascular disease. Although endothelial cells are enriched for miR-126, platelets also contain miR-126. In this paper, we investigated the contribution of platelets to the pool of miR-126 in plasma of patients with type 2 diabetes (DM2) and how this is affected by aspirin. %26lt;br%26gt;In vitro platelet activation resulted in the transfer of miR-126 from the platelet to the plasma compartment, which was prevented by aspirin. In vivo platelet activation, monitored in patients with DM2 by measuring soluble P-selectin, correlated directly with circulating levels of miR-126. The administration of aspirin resulted both in platelet inhibition and concomitantly reduced circulating levels of platelet-derived microRNAs including miR-126. %26lt;br%26gt;Platelets are a major source of circulating miR-126. Consequently, in patho-physiological conditions associated with platelet activation, such as diabetes type 2, the administration of aspirin may lead to reduced levels of circulating miR-126. Thus, the use of platelet inhibitors should be taken into account when using plasma levels of miR-126 as a biomarker.

• 出版日期2013-11